Zonisamide

Epilepsy

Azurity PharmaceuticalsSmall moleculePhase 4 / ApprovedActive

BB

69/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 67/ 100
Competitive Position: 73/ 100

Competitive context

64 Active assets in the Epilepsy cohort.

Asset / Sponsor	Phase	Rating
Lamotrigine Assiut University	Phase 4	BBB
Lacosamide Second Affiliated Hospital of Guangzhou Medical University	Phase 4	BBB
Eslicarbazepine Acetate Bial - Portela C S.A.	Phase 4	BBB
Topiramate Université de Sherbrooke	Phase 4	BBB
Levetiracetam Beijing Tiantan Hospital	Phase 4	BBB

View all 50 →

Same molecule, other indications

Zonisamide is also rated in:

focal epilepsyActive

BBB

Indicative · Phase 4

74 / 100

migraine disorderActive

B

Indicative · Phase 4

63 / 100

epilepsy with generalized tonic-clonic seizuresActive

B

Indicative · Phase 4

62 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.